関連する実験動画
Updated: Feb 19, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
977
アルツハイマー病:診断と治療に関する臨床的な最新情報
Dror Shir1, Christian Lachner2,3
1Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States.
Neurologia i neurochirurgia polska
|February 17, 2026
まとめ
アルツハイマー病 アルツハイマー病 アルツハイマー病
科学分野:
- 神経学 神経学とは
- バイオマーカー バイオマーカー
- 認知症の研究 認知症の研究
背景:
- アルツハイマー病 (AD) は認知症の主な原因であり,認知能力の低下が特徴です.
- 人口の高齢化はADの罹患率を増加させ,医療システムに負担をかけています.
- ADの病理生理学とバイオマーカーの理解は,診断と治療に不可欠です.
研究 の 目的:
- 現在のアルツハイマー病の診断枠組みを見直す.
- ADの診断と治療における課題と機会を議論する.
- バイオマーカーと新しい治療法の臨床実践への統合を調査する.
主な方法:
- 臨床評価とバイオマーカーを含む現在の診断枠組みの分析.
- 先進的なイメージングと流体バイオマーカー分析のレビュー.
- アンチアミロイドモノクローナル抗体療法の評価とその実施の課題.
主要な成果:
- バイオマーカーの統合には,正確性と実用的な考慮のバランスをとる必要があります.
- 共同意思決定は,治療の選択肢に不可欠です.
- 抗アミロイド療法とタウを標的とした研究が有望である.
結論:
- バイオマーカー検査を統合するには,患者に注意深くリスク・ベネフィット分析を行う必要があります.
- 拡張可能で非侵襲的なバイオマーカーは,診断のワークフローを変革することができます.
- 研究と臨床の架け橋となるには,学際的な協力が不可欠です.
関連する概念動画
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Dementia
591
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
591
Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Atherosclerosis III: Management
460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460

